Novo Nordisk and its profit-growth plans hit a roadblock earlier this year when the FDA refused to approve its new diabetes drug, Tresiba, without a new safety study. But CEO Lars Sorensen thinks he has an alternate route through a new weight-loss indication for the already top-selling Victoza.
When can a drugmaker beat earnings expectations and project a 10% boost in profits for the year and still end up disappointing investors? When that drugmaker is Novo Nordisk, the world's largest insulin maker, focused on a rapidly growing treatment area with investors expecting more, more, more.
Drugmakers, livid with German pricing gatekeepers for turning down so many new drugs, now face a strategy that is sure to ratchet up their anger to the boiling point.
A safety watchdog group has analyzed the FDA's adverse event data on the entire GLP-1 class of diabetes drugs, finding more reports of pancreatitis and pancreatic cancer for these drugs compared with older treatments.
Danish drugmaker Novo Nordisk sees potential to fatten the company's revenues by selling a diabetes drug to help the morbidly obese thin down.
The GLP-1 agonist bested Merck's Januvia and Amylin Pharmaceuticals' Byetta once again, this time by helping more patients push their blood sugar levels below a target of 7%.
Novo Nordisk racked up another set of positive data for its diabetes drug Victoza. The GLP-1 agonist bested Merck's Januvia and Amylin Pharmaceuticals' Byetta once again, this time by helping more patients push their blood sugar levels below a target of 7%.
Novo Nordisk ($NVO) is still going gangbusters. The Danish drugmaker hiked its earnings guidance for the year as it unveiled a 40% increase in core profits for the first 9 months, aided by a whopping 62% increase in sales of its diabetes drug Victoza. Overall sales increase? 18%.
Bristol-Myers Squibb ($BMY) and AstraZeneca ($AZN) dispatching legions of sales reps to tout Byetta and Bydureon? Bring it on, says Novo Nordisk's ($NVO) Mads Krogsgaard Thomsen. The Danish company's chief scientific officer told Bloomberg that more talk about that class of diabetes drugs will help Novo, too.
Sanofi is making a case for why its experimental diabetes drug Lyxumia stands out from existing GLP-1 therapies, as the French drug giant eyes the new med to build up its Lantus-led diabetes franchise amid relentless competition.